ICTCAR-023

N/A

Report date: 2022/04/11 16:43:59

Base Information

Drug NameICTCAR-023
Drug Alias NamedPD-1 (TSHR+CD19) CART cellsICTCAR-023
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionThyroid stimulating hormone receptor modulatorsB-lymphocyte antigen CD19 modulatorsImmunologic cytotoxicity +[4] 
TargetsThyroid stimulating hormone receptorB-lymphocyte antigen CD19
Therapy Area/IndicationsThyroid Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesInnovative Cellular Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHenan Provincial Cancer HospitalThird Affiliated Hospital Sun Yat-Sen University
Active IndicationsN/A
Inactive IndicationsThyroid Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A